(RGEN) Repligen - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 6.037m USD | Total Return: -16.5% in 12m

Filtration, Chromatography, Process Analytics, Proteins
Total Rating 38
Safety 84
Buy Signal -0.32
Medical Instruments & Supplies
Industry Rotation: +2.0
Market Cap: 6.04B
Avg Turnover: 148M
Risk 3d forecast
Volatility54.7%
VaR 5th Pctl9.00%
VaR vs Median-0.20%
Reward TTM
Sharpe Ratio-0.29
Rel. Str. IBD8.4
Rel. Str. Peer Group21.7
Character TTM
Beta0.859
Beta Downside0.795
Hurst Exponent0.473
Drawdowns 3y
Max DD50.64%
CAGR/Max DD-0.27
CAGR/Mean DD-0.54
EPS (Earnings per Share) EPS (Earnings per Share) of RGEN over the last years for every Quarter: "2021-03": 0.68, "2021-06": 0.79, "2021-09": 0.78, "2021-12": 0.81, "2022-03": 0.92, "2022-06": 0.91, "2022-09": 0.77, "2022-12": 0.68, "2023-03": 0.64, "2023-06": 0.53, "2023-09": 0.23, "2023-12": 0.33, "2024-03": 0.28, "2024-06": 0.33, "2024-09": -0.0117, "2024-12": 0.44, "2025-03": 0.39, "2025-06": 0.37, "2025-09": 0.46, "2025-12": 0.49, "2026-03": 0.48,
EPS CAGR: -15.68%
EPS Trend: -47.4%
Last SUE: 0.25
Qual. Beats: 0
Revenue Revenue of RGEN over the last years for every Quarter: 2021-03: 142.837, 2021-06: 162.96, 2021-09: 178.216, 2021-12: 186.521, 2022-03: 206.4, 2022-06: 207.633, 2022-09: 200.741, 2022-12: 186.762, 2023-03: 165.38, 2023-06: 159.169, 2023-09: 141.192, 2023-12: 155.743, 2024-03: 153.182, 2024-06: 154.073, 2024-09: 154.871, 2024-12: 167.547, 2025-03: 169.172, 2025-06: 182.366, 2025-09: 188.805, 2025-12: 197.913, 2026-03: 194.255,
Rev. CAGR: -1.76%
Rev. Trend: 6.8%
Last SUE: 0.70
Qual. Beats: 0

Warnings

P/E ratio 117.6

Tailwinds

No distinct edge detected

Description: RGEN Repligen

Repligen Corporation (NASDAQ: RGEN) is a Massachusetts-based life sciences company specializing in bioprocessing technologies for the development and manufacturing of biological drugs. Its product portfolio spans four primary areas: filtration, chromatography, protein ligands, and process analytics. These tools are critical for biopharmaceutical companies and contract manufacturing organizations (CMOs) to purify and scale the production of complex therapies, including monoclonal antibodies and gene therapies.

The company operates within the high-barrier Life Sciences Tools & Services sector, where its business model relies heavily on recurring revenue from single-use consumables. These consumables, such as chromatography resins and filtration cassettes, must be replaced frequently during the drug manufacturing process to maintain sterility and regulatory compliance. Repligen also maintains a strategic collaboration with Navigo Proteins GmbH to expand its ligand development capabilities for new drug modalities.

For a deeper dive into these business segments and historical performance, consider checking the detailed data on ValueRay.

Headlines to Watch Out For
  • Bioprocessing demand recovery in China and North America drives top-line revenue growth
  • Adoption of single-use technologies increases recurring consumable sales and operating margins
  • Expansion into cell and gene therapy markets diversifies long-term revenue streams
  • Biopharmaceutical capital expenditure cycles directly impact equipment and chromatography system sales
  • Strategic acquisitions and R&D investment levels influence competitive positioning and valuation
Piotroski VR‑10 (Strict) 4.0
Net Income: 51.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.65 > 1.0
NWC/Revenue: 135.6% < 20% (prev 136.4%; Δ -0.76% < -1%)
CFO/TA 0.04 > 3% & CFO 130.7m > Net Income 51.4m
Net Debt (105.0m) to EBITDA (182.8m): 0.57 < 3
Current Ratio: 9.20 > 1.5 & < 3
Outstanding Shares: last quarter (56.7m) vs 12m ago 0.19% < -2%
Gross Margin: 50.25% > 18% (prev 0.43%; Δ 4.98k% > 0.5%)
Asset Turnover: 26.40% > 50% (prev 22.64%; Δ 3.76% > 0%)
Interest Coverage Ratio: 1.97 > 6 (EBITDA TTM 182.8m / Interest Expense TTM 45.1m)
Altman Z'' 3.61
A: 0.35 (Total Current Assets 1.16b - Total Current Liabilities 126.2m) / Total Assets 2.93b
B: 0.16 (Retained Earnings 464.6m / Total Assets 2.93b)
C: 0.03 (EBIT TTM 89.1m / Avg Total Assets 2.89b)
D: 0.55 (Book Value of Equity 450.8m / Total Liabilities 825.3m)
Altman-Z'' Score: 3.61 = AA
Beneish M -3.19
DSRI: 0.87 (Receivables 151.6m/147.4m, Revenue 763.3m/645.7m)
GMI: 0.85 (GM 50.25% / 42.72%)
AQI: 0.97 (AQ_t 0.51 / AQ_t-1 0.52)
SGI: 1.18 (Revenue 763.3m / 645.7m)
TATA: -0.03 (NI 51.4m - CFO 130.7m) / TA 2.93b)
Beneish M-Score: -3.19 (Cap -4..+1) = AA
What is the price of RGEN shares? As of May 16, 2026, the stock is trading at USD 102.87 with a total of 2,307,248 shares traded.
Over the past week, the price has changed by -16.68%, over one month by -22.03%, over three months by -24.03% and over the past year by -16.54%.
Is RGEN a buy, sell or hold? Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.
  • StrongBuy: 10
  • Buy: 4
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RGEN price?
Analysts Target Price 179.8 74.8%
Repligen (RGEN) - Fundamental Data Overview as of 14 May 2026
P/E Trailing = 117.6154
P/E Forward = 62.5
P/S = 8.5653
P/B = 3.3063
P/EG = 1.9515
Revenue TTM = 763.3m USD
EBIT TTM = 89.1m USD
EBITDA TTM = 182.8m USD
Long Term Debt = 542.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 21.1m USD (from shortTermDebt, last quarter)
Debt = 687.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 105.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.94b USD (6.04b + Debt 687.6m - CCE 784.5m)
Interest Coverage Ratio = 1.97 (Ebit TTM 89.1m / Interest Expense TTM 45.1m)
EV/FCF = 57.06x (Enterprise Value 5.94b / FCF TTM 104.1m)
FCF Yield = 1.75% (FCF TTM 104.1m / Enterprise Value 5.94b)
FCF Margin = 13.64% (FCF TTM 104.1m / Revenue TTM 763.3m)
Net Margin = 6.73% (Net Income TTM 51.4m / Revenue TTM 763.3m)
Gross Margin = 50.25% ((Revenue TTM 763.3m - Cost of Revenue TTM 379.8m) / Revenue TTM)
Gross Margin QoQ = 50.70% (prev 47.21%)
Tobins Q-Ratio = 2.03 (Enterprise Value 5.94b / Total Assets 2.93b)
Interest Expense / Debt = 0.87% (Interest Expense 6.00m / Debt 687.6m)
Taxrate = 21.62% (13.5m / 62.4m)
NOPAT = 69.8m (EBIT 89.1m * (1 - 21.62%))
Current Ratio = 9.20 (Total Current Assets 1.16b / Total Current Liabilities 126.2m)
Debt / Equity = 0.33 (Debt 687.6m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.57 (Net Debt 105.0m / EBITDA 182.8m)
Debt / FCF = 1.01 (Net Debt 105.0m / FCF TTM 104.1m)
Total Stockholder Equity = 2.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.78% (Net Income 51.4m / Total Assets 2.93b)
RoE = 2.46% (Net Income TTM 51.4m / Total Stockholder Equity 2.09b)
RoCE = 3.39% (EBIT 89.1m / Capital Employed (Equity 2.09b + L.T.Debt 542.2m))
RoIC = 2.66% (NOPAT 69.8m / Invested Capital 2.62b)
WACC = 8.15% (E(6.04b)/V(6.72b) * Re(9.0%) + D(687.6m)/V(6.72b) * Rd(0.87%) * (1-Tc(0.22)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.54%
[DCF] Terminal Value 81.10% ; FCFF base≈110.4m ; Y1≈136.1m ; Y5≈232.3m
[DCF] Fair Price = 66.78 (EV 3.87b - Net Debt 105.0m = Equity 3.77b / Shares 56.4m; r=8.15% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -47.37 | EPS CAGR: -15.68% | SUE: 0.25 | # QB: 0
Revenue Correlation: 6.82 | Revenue CAGR: -1.76% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.45 | Chg30d=-2.89% | Revisions=-50% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=-8.73% | Revisions=-68% | Analysts=16
EPS current Year (2026-12-31): EPS=2.00 | Chg30d=+1.87% | Revisions=+79% | GrowthEPS=+17.0% | GrowthRev=+11.6%
EPS next Year (2027-12-31): EPS=2.55 | Chg30d=+2.60% | Revisions=+33% | GrowthEPS=+27.6% | GrowthRev=+14.7%
[Analyst] Revisions Ratio: +79%